I

nvesting in biotech startups is a laborious business.

Venture capitalists spend months poring over data before deciding whether to back a fledgling company. They’ll scour the scientific literature for signs that the core ideas are valid. They’ll call in the founding team for interminable grillings. They may even hire outside researchers to try to replicate key experiments.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.